"We continue to think the
administration will seek to drive greater pass-through of rebates to patients
at the point-of-care rather than handicap plan sponsors' ability to negotiate
with manufacturers."
— George Hill of RBC Capital Markets, LLC, talked with AIS's RADAR on Drug Benefits
about speculation that CMS's latest Part D rule could be the much-discussed
"safe harbor rule" that may upend the PBM-drug manufacturer rebate
system.
No comments:
Post a Comment